Jiangsu Recbio Technology Co., Ltd. (2179.HK)
HKD 8.0
(-3.38%)
HKD 8.0
(-3.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -617.74 Million CNY | 16.06% |
| 2022 | -735.96 Million CNY | -20.17% |
| 2021 | -612.45 Million CNY | -314.75% |
| 2020 | -147.66 Million CNY | -102.97% |
| 2019 | -72.75 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -126.43 Million CNY | 0.0% |
| 2024 Q1 | -126.43 Million CNY | 13.1% |
| 2023 Q4 | -145.49 Million CNY | 0.0% |
| 2023 FY | -617.74 Million CNY | 16.06% |
| 2023 Q2 | -163.37 Million CNY | 0.0% |
| 2023 Q3 | -145.49 Million CNY | 10.94% |
| 2023 Q1 | -163.37 Million CNY | 26.1% |
| 2022 Q2 | -216.47 Million CNY | 0.0% |
| 2022 Q1 | -216.47 Million CNY | -56.45% |
| 2022 FY | -735.96 Million CNY | -20.17% |
| 2022 Q4 | -221.06 Million CNY | 0.0% |
| 2022 Q3 | -221.06 Million CNY | -2.12% |
| 2021 FY | -612.45 Million CNY | -314.75% |
| 2021 Q3 | -194.47 Million CNY | -36.32% |
| 2021 Q2 | -142.66 Million CNY | 0.0% |
| 2021 Q1 | -142.66 Million CNY | -64.48% |
| 2021 Q4 | -138.36 Million CNY | 28.85% |
| 2020 Q4 | -86.73 Million CNY | 0.0% |
| 2020 FY | -147.66 Million CNY | -102.97% |
| 2019 FY | -72.75 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 1011.56% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 168.795% |